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Erythropoietin is a hypoxia-induced cytokine that stimulates erythropoiesis through the promotion of erythroid 
precursor cell proliferation and differentiation. Recent evidence supports that erythropoietin has a broad spec-
trum of tissue protecting actions affecting other systems than hemopoietic. Lately, research has focused on the 
nonhemopoietic effects of erythropoietin against tissue ischemia due to the unexpected observations of erythro-
poietin receptor expression by various cells, such as endothelial cells, neuronal cells, cardiac myocytes, and vas-
cular smooth muscle cells. It has been shown that erythropoietin exerts its cardioprotective action during cardiac 
ischemic injury through reducing the infract size and enhancing new vessel formation over a longer time frame. 
Erythropoietin plays a crucial role in neuroprotection in many types of ischemic injury in the central and the 
peripheral nervous system. It is also strongly believed that erythropoietin exhibits a critical role in many other 
disorders that are pathogenetically related to acute tissue ischemia. This article reviews the proposed implica-
tions of erythropoietin in tissue ischemia and discusses the possible mechanisms for this action along with its 
potential therapeutic applications. 
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1. Introduction 
Erythropoietin is a 165 aminoacid glycoprotein 
hormone with approximately 30 kD molecular weight. 
It is synthesized primarily by kidneys in adults and by 
kidneys and liver in the fetus. The ratio between kid-
ney and liver erythropoietin in the adult is 9:1 [1]. Its 
primary role involves prevention of programmed cell 
death (apoptosis) of erythrocyte precursors [2]. 
Erythropoietin induces erythropoiesis by promoting 
proliferation and differentiation of erythroid progeni-
tor cells with the main target cell being the col-
ony-forming unit erythroid (CFU-E). Although 
erythropoietin is the main regulator of this process, 
other growth factors, such as granulocyte col-
ony-stimulating factor (G-CSF), stem cell factor (SCF), 
interleukins IL-1, IL-3, IL-6 IL-4, IL-9, and IL-11, 
granulocyte-macrophage  (GM)-CSF, and insulin 
growth factor-1 (IGF-1) are believed that contribute in 
different levels of maturation of the erythrocyte [3, 4]. 
Erythropoietin gene expression is regulated 
mainly by hypoxia [5, 6]. Hypoxia-inducible factors 
(HIF) 1, 2 and 3, as well as nuclear factor kappa B 
(NF-kB) are the key regulators of erythropoietin gene 
expression [7]. Recent data revealed that hy-
poxia-inducible factor 2a (HIF-2a) has prominent role 
in controlling erythropoietin gene expression in he-
patic cells [8, 9]. According to some investigators this 
role of HIF-2a may be also applied in other tissues 
[10,11]. 
In addition to its well known effect on red blood 
cell mass in response to changes in tissue oxygenation, 
many investigations have shown that erythropoietin 
also exerts protective role against tissue ischemia. It is 
believed that this is achieved both directly by activat-
ing multiple biochemical mechanisms that provide 
antiapoptotic, antioxidative, and anti-inflammatory 
response to hypoxia/anoxia and indirectly via its an-
giogenic potential by inducing oxygen systematic 
supply to the ischemic tissue. 
This article reviews the proposed implications of 
erythropoietin in tissue ischemia and discusses the 
possible mechanisms for this action along with its po-
tential therapeutic applications. 
2. Non Erythropoietic Role of Erythropoietin 
Erythropoietin has a broad spectrum of tissue 
protecting actions affecting other systems than he-
mopoietic [12-15]. Beginning with the unexpected ob-
servations of erythropoietin receptor (Epo-R) expres-
sion by various cells, such as endothelial cells, neu-
ronal cells, cardiac myocytes, and vascular smooth 
muscle cells [16-19], research lately focused on the 
nonhemopoietic effects of erythropoietin and its po-




Erythropoietin exerts its cardioprotective action 
during cardiac ischemic injury through reducing the 
infract size and enhancing new vessel formation over a 
longer time frame [20]. It is well known that erythro-
poietin induces vasoconstriction-dependent hyperten-
sion and stimulation of angiogenesis in erythropoi-
etin-treated animals and humans [21]. The effect of 
erythropoietin in blood pressure has been extensively 
described in the past after the initiation of treating 
anemia in chronic renal failure patients [22-24]. The 
exact mechanism remains unclear, though, different 
hypotheses involving cyclooxygenase-dependent en-
dothelium derived contracting factors (EDCFs), 
stimulation of vascular cell growth, endogenous vaso-
dilatory factors, and a direct angioconstrictive action of 
erythropoietin have been described [25, 26]. Erythro-
poietin effect on heart disorders has been showed that 
involves a mechanism with greater immediacy than 
that of direct oxygen supply due to haemoglobin levels 
increase [27]. 
Silverberg et al. [28] evaluated the influence of 
recombinant erythropoietin in patients with chronic 
cardiac failure and suggested that erythropoietin us-
age improves both cardiac and renal function, while it 
decreases mortality rates and hospitalization due to 
heart failure. Similar observational studies in the past, 
have reported better clinical outcome, improvement of 
survival and lower complication rate when erythro-
poietin is administrated to patients undergoing 
hemodialysis in order to normalize haemoglobin levels 
[29, 30]. On the contrary, recent evidence from ran-
domised trials showed an increased risk of cardio-
vascular events and increased mortality in the same 
patient group [31, 32]. Bearing in mind the high cost of 
erythropoietin treatment and the insecure outcome in 
patient life expectancy, scepticism over the benefits of 
excessive use of erythropoietin is necessary. 
Erythropoietin exerts both acute and long term 
cardioprotective effects through its receptor. In vitro 
studies have shown that Epo-R is expressed in various 
cell lines originated from the cardiovascular system 
[16, 33, 34]. The presence of Epo-R was demonstrated 
in rat cardiac myocytes where the administration of 
erythropoietin prevented apoptosis by activating 
phosphatidylinositol 3 kinase (PI3-K)/Akt intracellu-
lar pathway [33]. According to Depping et al. [35] the 
expression of Epo-R was confirmed in ventricular 
myocytes and endothelial cells in adult human heart. 
Apoptotic mechanisms are considered to be as-
sociated with crucial cardiac cell death following 
myocardial infraction that potentially is complicated 
with cardiac failure [36, 37]. Inhibition of apoptosis has 
been strongly correlated with erythropoietin-mediated 
cardioprotection against acute ischemic injury. The 
antiapoptotic effects of erythropoietin have been asso-
ciated with the inactivation of Bcl-2 associated 
death-promoting protein (BAD) through PI3-K/Akt 
pathway as well as the increased expression of the 
antiapoptotic proteins Bcl-2 and Bcl-XL [20, 38]. In a rat 
isolated-heart model, pre-treatment with erythropoi-
etin increased the functional recovery of hearts during 
ischemia/reperfusion injury [39]. Further studies 
showed that specific pathways, such as PI3-K/Akt, 
mitogen-activated protein kinase (MAPK) pathways 
and protein kinase C (PKC) are implicated in 
erythropoietin cardioprotective action before, during 
or after ischemia [40-42]. 
Although apoptosis prevention is a main mecha-
nism for erythropoietin acute cardioprotection, the role 
of nitric oxide (NO), a modulator of vascular tone and 
inhibitor of processes involved in atherothrombosis, 
should also be considered [43-45]. The endothelial 
isoform of NO is the prevailing form in the cardio-
vascular system. Endothelial nitric oxide synthase 
(eNOS) is activated by the signal transducer and acti-
vator of transcription-5 (STAT-5) and RAS/MAPK 
signalling molecules. In a transgenic mice model 
overexpressing human erythropoietin, the authors 
demonstrated fail to develop hypertension and myo-
cardial infraction [46]. This was attributed to 
up-regulation of eNOS expression, increased NO 
production, and NO-mediated vascular relaxation 
compared to wild type animals. 
Long–term protection of ischemic myocardium 
by erythropoietin is attributed to both new vascular 
formations by directly enhancing angiogenesis and 
increased vasculogenesis from endothelial progenitor 
cells (EPCs) [20]. It has been found that erythropoietin 
promotes EPC mobilization which in turn was associ-
ated with neovascularization of ischemic tissue [47]. 
Interestingly, the number of circulating EPCs in pa-
tients with coronary artery disease was significantly 
correlated with serum levels of erythropoietin [47]. 
Moreover, erythropoietin promotes NO synthesis in 
EPCs and reendothelialization of injured arterial ves-
sels [48]. 
High-dose chronic erythropoietin treatment may 
result to increased hematocrit associated side effects, 
such as hypertension and thromboembolism. En-
hancement of erythropoietin cardiac tissue protective 
activity without increasing the number of red blood 
cells is the key in the management of heart disorders. 
Nervous System 
It has been shown that special pathways for 
erythropoietin and its receptor are present not only in 
the central nervous system but also in the peripheral 
nerves, cerebrospinal fluid, and the retina [49-53]. Int. J. Biol. Sci. 2008, 4 
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Erythropoietin is suggested to be a cytokine with a 
neurotrophic and a neuroprotective role in the central 
and peripheral nervous system. Several studies have 
shown the neuroprotective action of erythropoietin 
[13, 14], while others have demonstrated that 
erythropoietin may facilitate nerve regeneration after 
peripheral nerve injury [54]. This role in neural system 
appears to resemble the actions of erythropoietin in 
progenitor cells of the hematopoietic tissue and is 
thought to be multifactorial. Hypoxia and neurological 
damage enhance erythropoietin and Epo-R production 
in the central nervous system [52, 55, 56]. HIF-1, a 
member of the PAS (PER/arylhydrocabon-receptor 
nuclear translocator/single minded) family of hy-
poxia-regulated transcription factors is the main factor 
responsible for hypoxia-mediated induction of 
erythropoietin expression in the retina [57]. 
Despite previous evidence it is now believed that 
erythropoietin crosses the blood-brain barrier in an 
injured brain [58]. This evolution confirms the impor-
tance of erythropoietin role in the initial treatment of 
the acutely injured nervous tissue. Furthermore, it of-
fers an effective treatment for these conditions, since 
its intravenously or subcutaneous administration pro-
vides effective and targeted therapy. In addition, the 
results from the administration of recombinant human 
erythropoietin (rhEpo) in acute stroke patients con-
firmed exultantly both its safety and effectiveness in 
protecting cerebral tissue from ischemia [59]. 
Several hypotheses have been proposed in order 
to explicate the neuroprotective role of erythropoietin. 
Erythropoietin exhibits neurotrophic, 
anti-inflammatory, and antioxidant action [14, 49, 
60-63]. It has been shown that it decreases susceptibil-
ity to glutamate toxicity [64, 65] and promotes apop-
tosis through induction of apoptotic agents [14, 51, 
62-65].  Erythropoietin reduces nitric oxide-mediated 
injury [66-68], with its protective role on glia [69-71]. 
The improvement of blood flow to the injured tissue is 
a further potential mechanism of erythropoietin’s 
protective role in the nervous system. 
When a single molecule of erythropoietin binds 
its receptor enzymic phosphorylation of PI3-K and the 
nuclear factor NF-kB occurs. NF-kB, which is activated 
by erythropoietin after oxidotic stress [67], is an in-
flammatory reaction genes regulator [72]. Erythropoi-
etin activates JAK2, which in turn activates NF-kB re-
sulting in increased expression of apoptosis inhibiting 
genes, such as XIAP and c-IAP2. Activation of Akt by 
erythropoietin inhibits various metabolic paths that 
are connected to cell death, such as those which are 
related to glycogen synthetase kinase 3β (GSK3β), re-
lated to BAD, caspase-9, etc [73]. Furthermore, JAK2 
induces activation by phosphorylation of Jun kinase 
(JNK) and signal transducers and activators of tran-
scription-5 (STAT-5) [74, 75]. STAT-5 enters the nu-
cleus and induce transcription of genes involved with 
inhibition of apoptosis, such us Bcl-xL genes [74]. 
In the recent years, increasing knowledge of the 
nervous system physiology allowed the analysis of the 
pathogenetic mechanisms involved in various abnor-
mal conditions. Disorders such as early brain injury, 
attention deficit hyperactivity disorder, and retinopa-
thy of prematurity have been etiologically related to 
hypoxia. Erythropoietin actions seem to reverse this 
hypoxia-induced sequelae. A recent study proposed 
potential benefit by erythropoietin administration in 
patients with various psychiatric disorders [76]. Such 
an ischemic etiological profile may alternate not only 
the treatment approach used so far, but could also 
develop a new dynamic in the research of pathogenetic 
factors of vague disorders, such as Alzheimer’s dis-
ease. 
Other Roles Proposed for Erythropoietin 
Based on observations on the role of erythropoi-
etin in other tissues, it is strongly believed that 
erythropoietin plays a critical role in disorders that are 
pathogenetically related to acute tissue ischemia. 
Erythropoietin has been used in the past for cor-
recting both cancer and chemotherapy induced anemia 
[77-80]. Furthermore, the treatment outcome of both 
radiotherapy and chemotherapy in cancer patients 
receiving erythropoietin seems to be superior based on 
the beneficial effects of erythropoietin to tumour hy-
poxia [81]. However, the expression of erythropoietin 
receptor in neoplasmatic cells initially raised the ques-
tion whether erythropoietin promotes tumour growth. 
Recently, Hamadmad and Holh [82] demonstrated 
that erythropoietin induces chemotaxis of cancer cells 
via MAPK/Erk and Rho/RhoA kinase pathways. 
These reports are in accordance with the finding from 
a trial conducted by Leyland-Jones et al. [83] where the 
usage of erythropoietin for the treatment of anemia in 
metastatic breast cancer patients resulted in decreased 
survival. In the same study, the primary cause of death 
in erythropoietin group was disease progression, sig-
nificantly higher than the control group. 
Although these reports are not debating the posi-
tive affects of erythropoietin, they make the need for 
further research in this field essential [84]. A recent 
meta-analysis confirmed the increased risk of venous 
thromboembolism and increased mortality rates after 
erythropoietin administration [85]. Safety concerns 
over the usage of erythropoiesis stimulating agents in 
treating anemia in patients with cancer are well estab-
lished. Understanding the mechanism of the exact role 
of erythropoietin in neoplasmatic cells would possibly Int. J. Biol. Sci. 2008, 4 
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clarify these issues and potentially indicate alternative 
therapeutic measures against cancer. 
The protective role of erythropoietin in tissue 
ischemia extended the investigation of the potential 
role of erythropoietin in other conditions related with 
ischemia. In critical ill patients, erythropoietin has 
been proposed as an ameliorator of the clinical out-
come [86]. Studies suggesting the role of erythropoi-
etin in survivor of skin and muscular flaps in animal 
studies magnify the significance of this cytokine in 
trauma patients [87, 88]. 
Although erythropoietin failed to reduce red 
blood cell transfusions in critically ill patients, it finally 
declined mortality in this group of patients with a 
higher decrease applied in trauma patients [86]. Since 
there was no difference in blood transfusion rate, the 
decrease in the mortality rate is not considered as a 
consequence of blood transfusion. The contribution of 
a nonhematopoietic mechanism in the superior mor-
tality rate in erythropoietin treated patients is believed 
by the authors to be logical explanation to this contra-
dictory event. 
The presence of erythropoietin receptor in retina 
establishes a major role to erythropoietin in the treat-
ment of several pathologic conditions etiological re-
lated to ischemia in these highly oxygen dependent 
tissue. Despite the discouraging results reported in 
non randomised trials exploring the results of 
erythropoietin in retinopathy [89], a new dynamic has 
been developed as knowledge on erythropoietin and 
nervous system advances [90]. Further study is needed 
in order to clarify the role of this ischemia protective 
cytokine in conditions, such as diabetic retinopathy 
and retinopathy of prematurity. 
The role of angiogenic potential on survival of 
various flaps after erythropoietin administration has 
been extensively investigated. It is known that 
erythropoietin results in neovascularization and in-
creased healing through stimulation of endothelial cell 
mitosis [88]. According to Jaquet et al. [91] erythropoi-
etin found to have equal angiogenic potential with 
vascular endothelial growth factor (VEGF) which was 
confirmed by histologic evaluation on flaps. Moreover, 
exogenous administration of erythropoietin stimulated 
angiogenesis by day 3 in a genetically diabetic mouse 
model by increasing VEGF mRNA and protein ex-
pression [92]. However, Kim et al. [93] supported that 
the angiogenic potential of erythropoietin is unlikely 
to occur in the first 24 hours and therefore is not suffi-
cient enough to explain the protective effect of 
erythropoietin on ischemia/reperfusion injury in their 
rat transverse rectus abdominis musculocutaneous 
(TRAM) flap model. 
Novel erythropoiesis stimulating protein (NESP) 
or darbepoetin alfa has been introduced for the treat-
ment of anemia in several conditions with comparable 
results with those of erythropoietin. It has a different 
pharmacokinetic profile from erythropoietin that al-
lows less frequent administration in order to maintain 
similar haemoglobin levels [94-98]. Since the mecha-
nism of action of NESP is relevant to the one of 
erythropoietin, its role in other tissues remains to be 
explored. Further study is needed before establishing 
the exact role of both erythropoietic inducing factors in 
tissue ischemia. Based on the disadvantages of high 
cost and potential low safety profile of recombinant 
erythropoiesis-stimulating agents in some patient 
groups, the potential benefit of interfering in erythro-
poietin gene expression through HIF-2 mechanisms 
emerges as an alternative for the treatment of certain 
types of anemia. 
3. Erythropoietin in Ischemia/Reperfusion In-
jury 
Reperfusion injury is defined as the tissue injury 
following restoration of blood flow to an ischemic re-
gion. Ischemia/reperfusion-induced injury is charac-
terized by a greater rate of tissue damage than the 
original ischemic insult itself and it is thought to be the 
result of the acute interruption of blood flow within 
the microcirculation. The injury is attributed to a com-
plex interaction between neutrophils and endothelial 
cells when the formers release enzymes, free radicals, 
and cytokines [99]. This cascade usually leads to en-
dothelium destruction, capillary obstruction, and fi-
nally to impairment of oxygen supply to the tissue 
[100-103]. 
Many studies have demonstrated that erythro-
poietin has a protective effect on tissue injury associ-
ated with ischemia/reperfusion injury in many tissues, 
including brain, retina, cardiac, liver, kidney, lung, and 
intestine [104-109]. This erythropoietin mediated pro-
tective effect against ischemia/reperfusion injury has 
been related to its antiapoptotic, antioxidative, and 
antiiflammatory properties. 
Although apoptosis serves to eliminate dying 
cells in proliferating or differentiating cell populations 
[110], inappropriate induction of programmed cell 
death in pathologic conditions, such as ische-
mia/reperfusion injury, results in tissue dysfunction. 
Previous studies have shown that rhEpo protects 
against the ischemia/reperfusion injury, mainly 
through its antiapoptotic action [105, 109, 111]. Ac-
cording to Brimes and Gerami [112], the mechanism 
mediating the antiapoptotic effects of erythropoietin 
probably incudes the JAK2-STAT-Bcl-2 pathway. Int. J. Biol. Sci. 2008, 4 
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Bcl-2 may also be responsible for the antioxidant 
activity of erythropoietin [67]. It is believed that 
erythropoietin exhibits its antioxidant action either 
directly through the scavenging action of its 
sugar-moiety or indirectly by activating antioxidant 
enzymes, such as catalase (CAT), superoxide dismu-
tase (SOD), and glutathione peroxidase (GSH-Px) [109, 
113-118]. In an intestinal ischemia/reperfusion injury 
model in rats, Guneli et al. [109] revealed that although 
enzymatic activity of SOD and GSH-Px was not sig-
nificantly changed after intraperitoneal administration 
of erythropoietin, significant alterations were obtained 
in the level of CAT activity. The authors concluded 
that erythropoietin may be capable to increase the ac-
tivity of the antioxidant system via the increase or 
restoration of CAT levels which decreases due to 
ischemia/reperfusion injury. 
Oxidative stress is an important determinant in 
the pathogenesis of ischemia/reperfusion injury. Ac-
cumulation of activated neutrophils at the injury site 
triggers the inflammatory cascade through the pro-
duction of various cytotoxic proteins which in turn 
promote the radical induced ischemia/reperfusion 
injury [119-121]. Erythropoietin by suppressing the 
inflammatory response after the ischemia/reperfusion 
injury seems to be a protective agent in tissues sub-
jected to this type of damage [65, 122, 123]. Erythro-
poietin mediated neutropenia reversal following 
reperfusion is believed to b e  t h e  u n d e r l y i n g  m e c h a -
nism for the inhibition of neutrophil recruitment in the 
inflamed tissue. 
The role of erythropoietin on eNOS is still con-
troversial. It is supported that although eNOS-derived 
NO may play a protective role at the onset of ische-
mia/reperfusion injury, the superoxide anions pro-
duced during oxidative stress may react with NO and 
turn it into oxidant peroxynitrite which is cytotoxic 
[124, 125]. Many authors have shown that eNOS pro-
duction and eNOS-derived NO overproduction is de-
creased after erythropoietin administration [66, 109, 
126-128]. However, other investigators have reported 
increased expression of eNOS after erythropoietin 
therapy [129]. Therefore, before direct conclusions can 
be made, the role of erythropoietin in eNOS expression 
after ischemia/reperfusion injury should be eluci-
dated. 
4. Conclusion 
Erythropoietin is believed to serve a manifold 
role in several tissues with the primary target being the 
protection from ischemia. It acts both by ensuring 
adequate oxygen supply through its role to erythro-
poiesis but also it intervenes directly to the tissue tar-
gets with multiple set of actions that reserve cell sur-
vivor through its nonhematopoietic effects. Further 
research would provide us with evidence that could 
alter the way erythropoietin is currently used in the 
clinical practice. 
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